Service Utilization Patterns and Direct Medical Costs of Hospitalization in Patients With Renal Failure Before and After Initiating Home Peritoneal Dialysis.

OBJECTIVES: This study aimed to determine the hospital service utilization patterns and direct healthcare hospital costs before and during peritoneal dialysis (PD) at home. METHODS: A retrospective cohort study of patients with kidney failure (KF) was conducted at a Mexican Social Security Institute hospital for the year 2014. Cost categories included inpatient emergency room stays, inpatient services at internal medicine or surgery, and hospital PD. The study groups were (1) patients with KF before initiating home PD, (2) patients with less than 1 year of home PD (incident), and (3) patients with more than 1 year of home PD (prevalent). Costs were actualized to international dollars (Int$) 2023. RESULTS: We found that 53% of patients with KF used home PD services, 42% had not received any type of PD, and 5% had hospital dialysis while waiting for home PD. The estimated costs adjusting for age and sex were Int$5339 (95% CI 4680-9746) for patients without home PD, Int$17 556 (95% CI 15 314-19 789) for incident patients, and Int$7872 (95% CI 5994-9749) for prevalent patients; with significantly different averages for the 3 groups (P < .001). CONCLUSIONS: Although the use of services and cost is highest at the time of initiating PD, over time, using home PD leads to a significant reduction in use of hospital services, which translates into institutional cost savings. Our findings, especially considering the high rates of KF in Mexico, suggest a pressing need for interventions that can reduce healthcare costs at the beginning of renal replacement therapy.

Direct medical cost of COVID-19 in children hospitalized at a tertiary referral healthcare center in Mexico City.

Introduction: Despite the end of the COVID-19 pandemic being declared by the WHO, the economic consequences are far from over. One of these implications was the cost of inpatient care for health institutions. To date, some studies have examined the economic burden of COVID-19 in the adult population but only a few have focused on child populations. Objective: To estimate the direct medical costs of COVID-19, focusing on children in Mexico. Method: Data about resources consumed during hospital stays were extracted from the medical records of patients hospitalized at a Mexican tertiary healthcare institution. Other sources of information were the unit prices of inputs and the salaries of health personnel. A micro-costing methodology was used to obtain cost results by age group over different hospital areas. Data analysis was performed with descriptive statistics and regression models to evaluate the predictors of total cost. Results: One hundred and ten medical records were reviewed of which 57.3% corresponded to male patients and the mean age was 7.2 years old. The estimated average cost per patient was US$5,943 (95% CI: US$4,249-7,637). When the costs of the three clinical areas were summed, only the 5-10 years old group showed a maximum cost of US$14,000. The regression analysis revealed the following factors as significant: sex, age, staying at an emergency room, having a positive bacterial culture, and having comorbidities. Discussion: The cost results were somewhat similar to those reported in children from the USA, but only regarding low severity COVID-19 cases. However, comparability between these types of studies should be done with caution due to the huge differences between the healthcare systems of countries. The study cost results may help public decision-makers in budget planning and as inputs for future cost-effectiveness studies about interventions regarding COVID-19.

COVID-19 medical care direct costs during the first year of pandemic in a hospital converted for increasing bed capacity.

BACKGROUND: COVID-19 health emergency caused an increase in the demand for hospitalization and high costs for the health system. OBJECTIVE: To estimate COVID-19 care direct costs from the perspective of the healthcare provider in a secondary care hospital that underwent conversion during the first year of health emergency. MATERIAL AND METHODS: Retrospective, observational study. Information on quantities of goods and services was obtained from the SINOLAVE and CVOED platforms and from hospital administrative sources. Four cost groups were defined and estimated with 2021 unit prices in US dollars. RESULTS: Mean hospital length of stay (n = 3,241 patients) was 10.8 ± 8.2 days. Average cost of care per patient was USD 6,557 ± 4,997. Respiratory therapy with assisted mechanical ventilation was used by 13% of patients. CONCLUSIONS: The costs of COVID-19 medical care represent a large amount of resources. Most part of the costs (95%) were derived from hospital stay, respiratory therapy without assisted mechanical ventilation and costs related to personal protective equipment, hygiene, infrastructure adaptation and payments to medical personnel.

ANTECEDENTES: La emergencia sanitaria por COVID-19 causó un aumento de la demanda por hospitalización y costos elevados para el sistema de salud. OBJETIVO: Estimar los costos directos de la atención por COVID-19 desde la perspectiva del proveedor de servicios en un hospital de segundo nivel que fue reconvertido durante el primer año de la emergencia sanitaria. MATERIAL Y MÉTODOS: Estudio observacional retrospectivo. La información sobre cantidades de bienes y servicios se obtuvo de los sistemas de información SINOLAVE y CVOED, así como de fuentes administrativas del hospital. Se definieron cuatro grupos de costos y se valoraron en dólares norteamericanos con precios unitarios de 2021. RESULTADOS: La duración promedio de la estancia hospitalaria (n = 3241 pacientes) fue de 10.8 ± 8.2 días. El costo promedio de la atención por paciente fue de USD 6 557 ± 4 997. La terapia respiratoria con ventilación mecánica asistida fue utilizada por 13 % de los pacientes. CONCLUSIONES: Los costos médicos de atención por COVID-19 representaron una gran cantidad de recursos. La mayor parte de los costos (95 %) se derivó de estancia hospitalaria, terapia respiratoria sin ventilación mecánica asistida, así como de costos relacionados con equipo de protección personal, higiene, adecuación a la infraestructura y pagos al personal médico.

Costos directos de atención médica por COVID-19 durante el primer año de pandemia en un hospital reconvertido / COVID-19 medical care direct costs during the first year of pandemic in a hospital converted for increasing bed capacity

Resumen Antecedentes: La emergencia sanitaria por COVID-19 causó un aumento de la demanda por hospitalización y costos elevados para el sistema de salud. Objetivo: Estimar los costos directos de la atención por COVID-19 desde la perspectiva del proveedor de servicios en un hospital de segundo nivel que fue reconvertido durante el primer año de la emergencia sanitaria. Material y métodos: Estudio observacional retrospectivo. La información sobre cantidades de bienes y servicios se obtuvo de los sistemas de información SINOLAVE y CVOED, así como de fuentes administrativas del hospital. Se definieron cuatro grupos de costos y se valoraron en dólares norteamericanos con precios unitarios de 2021. Resultados: La duración promedio de la estancia hospitalaria (n = 3241 pacientes) fue de 10.8 ± 8.2 días. El costo promedio de la atención por paciente fue de USD 6 557 ± 4 997. La terapia respiratoria con ventilación mecánica asistida fue utilizada por 13 % de los pacientes. Conclusiones: Los costos médicos de atención por COVID-19 representaron una gran cantidad de recursos. La mayor parte de los costos (95 %) se derivó de estancia hospitalaria, terapia respiratoria sin ventilación mecánica asistida, así como de costos relacionados con equipo de protección personal, higiene, adecuación a la infraestructura y pagos al personal médico.

Abstract Background: COVID-19 health emergency caused an increase in the demand for hospitalization and high costs for the health system. Objective: To estimate COVID-19 care direct costs from the perspective of the healthcare provider in a secondary care hospital that underwent conversion during the first year of health emergency. Material and methods: Retrospective, observational study. Information on quantities of goods and services was obtained from the SINOLAVE and CVOED platforms and from hospital administrative sources. Four cost groups were defined and estimated with 2021 unit prices in US dollars. Results: Mean hospital length of stay (n = 3,241 patients) was 10.8 ± 8.2 days. Average cost of care per patient was USD 6,557 ± 4,997. Respiratory therapy with assisted mechanical ventilation was used by 13% of patients. Conclusions: The costs of COVID-19 medical care represent a large amount of resources. Most part of the costs (95%) were derived from hospital stay, respiratory therapy without assisted mechanical ventilation and costs related to personal protective equipment, hygiene, infrastructure adaptation and payments to medical personnel.

Cost-effectiveness analysis of a hand hygiene monitoring system in a tertiary pediatric hospital in Mexico.

Background: An automated hand-hygiene monitoring system (AHHMS) was implemented in October 2019 at the Hospital Infantil de México Federico Gómez (HIMFG), a tertiary pediatric referral hospital, in four of the hospital wards with the highest rates of Healthcare Associated Infections (HAIs). The clinical and economic impact of this system had not yet been assessed prior to this study. This study aimed to evaluate if the AHHMS is a cost-effective alternative in reducing HAIs in the HIMFG. Methodology: A full cost-effectiveness economic assessment was carried out for the hospital. The alternatives assessed were AHHMS implementation vis-a-vis AHHMS non-implementation (historical tendency). The outcomes of interest were infection rate per 1,000 patient-days and cost savings as a result of prevented infections. Infection rate data per 1,000 patient-days (PD) were obtained from the hospital's Department of Epidemiology with respect to the AHHMS. As regards historical tendency, an infection-rate model was designed for the most recent 6-year period. Infection costs were obtained from a review of available literature on the subject, and the cost of the implemented AHHMS was provided by the hospital. The assessment period was 6 months. The incremental cost-effectiveness ratio was estimated. Costs are reported in US Dollars (2021). Univariate sensitivity and threshold analysis for different parameters was conducted. Results: The total estimated cost of the AHHMS alternative represented potential savings of $308,927-$546,795 US Dollars compared to non-implementation of the system (US$464,102 v. US$773,029-$1,010,898) for the period. AHHMS effectiveness was reflected in a diminished number of infections, 46-79 (-43.4-56.7%) compared to non-implementation (60 v. 106-139 infections). Conclusion: The AHHMS was found to be a cost-saving alternative for the HIMFG given its cost-effectiveness and lower cost vis-a-vis the alternate option. Accordingly, the recommendation was made of extending its use to other areas in the hospital.

Análisis de costoefectividad de la oximetría de pulso como prueba de detección de las cardiopatías congénitas críticas en México.

OBJETIVO: Realizar un análisis de costoefectividad de la oximetría de pulso como prueba de detección neonatal de las cardiopatías congénitas críticas (CCC) en México. Material y métodos. Se realizó un estudio de evaluación económica desde la perspectiva de los proveedores de servicios de salud. A través de un árbol de decisiones se comparó la examinación física versus la examinación física junto con la prueba de oxi-metría de pulso (POP). RESULTADOS: Por cada 10 000 recién nacidos, la alternativa con la POP detectó 32 casos adicionales de CCC, con una razón de costoefectividad incremental de 1 219 USD y una probabilidad de costoefectividad mayor a 90% con una disposición a pagar de 25 000 USD por cada detección temprana. Conclusión. La costoefectividad de la POP, como tamiz neonatal cardiaco, es mayor en México que en países de altos ingresos, y representa una inversión costoefectiva para ganar años de vida en la población infantil de México.

Evolution of the stage of chronic kidney disease from the diagnosis of hypertension in primary care / Evolución del estadio de la enfermedad renal crónica desde el diagnóstico de hipertensión arterial en atención primaria

Objective: To analyze the evolution of the stages of CKD and the progression of the estimation of glomerular filtration rate (eGFR) in patients with newly diagnosed hypertension. Design-: Retrospective cohort.SiteFamily Medicine Unit No. 31, Mexican Social Security Institute, Mexico City. Participants: Patients with hypertension who have been diagnosed in primary care and have developed chronic kidney disease .Main measurements: The eGFR was calculated with the CKD Epi formula in three moments, the first measurement was at the time of diagnosis of hypertension, the second measurement was made when it arrived a change in CKD stage and the last one at the end of the study, with which the evolution time from one stage to another was obtained, as well as the drop in eGFR. Results: The sample consisted of 207 electronic health records of patients, with an average follow-up of 10.2 years from the moment of diagnosis of hypertension until the end of the study. The average time to go from one baseline stage of CKD to another was 7 years (average decline in eGFR of 5.8ml/min/year) and to have a second stage change was 3.2 years (average decline in eGFR of 6.8ml/min/year), with a statistically significant repeated measures ANOVA (p<0.001). Conclusions: Patients with newly diagnosed hypertension remain longer in the initial stages of CKD, to later evolve and change more quickly.(AU)

Objetivo: Analizar la evolución de los estadios de la enfermedad renal crónica (ERC) y la progresión de la estimación de la tasa de filtración glomerular (eTFG) en pacientes con hipertensión arterial de nuevo diagnóstico. Diseño: Cohorte retrospectiva. Emplazamiento: Unidad de Medicina Familiar N.° 31, Instituto Mexicano del Seguro Social, Ciudad de México. Participantes: Pacientes hipertensos que hayan sido diagnosticados en atención primaria y hayan desarrollado ERC. Mediciones principales: La eTFG se calculó con la fórmula CKD Epi en 3 momentos. La primera medición fue al momento del diagnóstico de hipertensión arterial, la segunda medición se realizó cuando se presentó un cambio de estadio de la ERC y la última, al final del estudio, con el que se obtuvo el tiempo de evolución de un estadio a otro, así como el descenso de la eTFG. Resultados: La muestra estuvo constituida por 207 historias clínicas electrónicas de pacientes, con un seguimiento promedio de 10,2 años desde el momento del diagnóstico de hipertensión arterial hasta el final del estudio. El tiempo promedio para pasar de una etapa inicial de la ERC a otra fue de 7 años (disminución promedio de la eTFG de 5,8ml/min/año) y para tener un cambio de segunda etapa fue de 3,2 años (disminución promedio de la eTFG de 6,8ml/min/año), con un ANOVA de medidas repetidas estadísticamente significativo (p < 0,001). Conclusiones: Los pacientes con hipertensión arterial de nuevo diagnóstico permanecen más tiempo en los estadios iniciales de la ERC, para luego evolucionar y cambiar más rápidamente.(AU)

Evolution of the stage of chronic kidney disease from the diagnosis of hypertension in primary care.

OBJECTIVE: To analyze the evolution of the stages of CKD and the progression of the estimation of glomerular filtration rate (eGFR) in patients with newly diagnosed hypertension. DESIGN: Retrospective cohort. SITE: Family Medicine Unit No. 31, Mexican Social Security Institute, Mexico City. PARTICIPANTS: Patients with hypertension who have been diagnosed in primary care and have developed chronic kidney disease. MAIN MEASUREMENTS: The eGFR was calculated with the CKD Epi formula in three moments, the first measurement was at the time of diagnosis of hypertension, the second measurement was made when it arrived a change in CKD stage and the last one at the end of the study, with which the evolution time from one stage to another was obtained, as well as the drop in eGFR. RESULTS: The sample consisted of 207 electronic health records of patients, with an average follow-up of 10.2 years from the moment of diagnosis of hypertension until the end of the study. The average time to go from one baseline stage of CKD to another was 7 years (average decline in eGFR of 5.8ml/min/year) and to have a second stage change was 3.2 years (average decline in eGFR of 6.8ml/min/year), with a statistically significant repeated measures ANOVA (p<0.001). CONCLUSIONS: Patients with newly diagnosed hypertension remain longer in the initial stages of CKD, to later evolve and change more quickly.

Cost analysis of drug treatment in hypertensive patients at social security health care family medicine units.

OBJECTIVE: To estimate the increase of drug treatment costs associated with predictive factors of hypertensive patients in family medicine units. MATERIALS AND METHODS: A generalized linear model was employed to estimate costs with data from a microcosting costing study for a 1-year time horizon. Sources of dada were medical electronic files, phar-macy records and unitary prices updated to 2019. RESULTS: From a total of 864 patients older than 65 years were 67% and women 65%. Factors with most influence on mean drug treatment costs were diabetes, age and complications associ-ated with hypertension. Mean annual cost of antihypertensive treatment was 61 dollars (CI95% 55,67) and median were 32 dollars (IQR 30,35) per patient. Incremental costs for diabetes were 23 dollars (CI95% 13,33) and 25 dollars (CI95% 5,45) in the group of ≥ 65 years. CONCLUSION: Diabetes, age and complications were the factors with largest influence on hypertension pharmacological costs.

Cost analysis of drug treatment in hypertensive patients at social security health care family medicine units / Análisis de costo de tratamientos farmacológicos en pacientes hipertensos en unidades de medicina familiar de seguridad social en salud

Abstract: Objective: To estimate the increase of drug treatment costs associated with predictive factors of hypertensive patients in family medicine units. Materials and methods: A generalized linear model was employed to estimate costs with data from a microcosting costing study for a 1-year time horizon. Sources of dada were medical electronic files, pharmacy records and unitary prices updated to 2019. Results: From a total of 864 patients older than 65 years were 67% and women 65%. Factors with most influence on mean drug treatment costs were diabetes, age and complications associated with hypertension. Mean annual cost of antihypertensive treatment was 61 dollars (CI95% 55,67) and median were 32 dollars (IQR 30,35) per patient. Incremental costs for diabetes were 23 dollars (CI95% 13,33) and 25 dollars (CI95% 5, 45) in the group of ≥ 65 years. Conclusion: Diabetes, age and complications were the factors with largest influence on hypertension pharmacological costs.

Resumen: Objetivo: Estimar el aumento de costos de tratamiento farmacológico de hipertensión asociado con factores predictivos en pacientes de unidades de medicina familiar. Material y métodos: El análisis utilizó un modelo lineal generalizado alimentado con información de un estudio de microcosteo en 2016. Las fuentes de información fueron los registros médicos del expediente electrónico y de farmacia y los precios unitarios del cuadro básico de medicamentos transformados a dólares americanos correspondientes a 2019. Resultados: Las variables significativas con mayor influencia fueron diabetes, edad y complicaciones asociadas con hipertensión. El costo promedio anual de tratamiento antihipertensivo por paciente fue de 61 dólares (IC95% 55,67) Los resultados sugieren un costo incremental de 23 dólares (IC95% 13,33) cuando se tiene diabetes y de 25 dólares (IC95% 5, 45) en el grupo ≥ 65 años. Conclusiones: Diabetes, edad y complicaciones son los factores encontrados que más influyen en los costos farmacológicos de tratamiento de la hipertensión.

Disability-Adjusted Life Years for the COVID-19 Pandemic in the Mexican Population.

Mexico is one of the countries most affected by the COVID-19 disease. Although there is vast information on the disease, there still are unknown data on the societal and economic cost of the pandemic. To estimate this impact, the disability-adjusted life years (DALYs) can be a useful tool. Objective: To assess the DALYs due to COVID-19 in Mexico. Methods: We used the data released by the Mexican Ministry of Health to estimate the DALYs by the sum of the years of life lived with disability (YLDs) and the years of life lost (YLLs). Results: A total of 1,152,885 confirmed cases and 324,570 suspected cases of COVID-19 have been registered. Half of the cases were men, with a median age of 43.4 ± 16.9 years. About 8.3% died. A total of 39,202 YLDs were attributable to COVID-19. The total YLLs caused by COVID-19 were 2,126,222. A total of 2,165,424.5 DALYs for COVID-19 were estimated. The total DALYs were the highest in people between 50 and 59 years. The DALYs for each COVID-19 case were the highest in individuals between 60 and 79 years. Conclusion: The DALYs generated by the COVID-19 represent a more significant disease burden than that reported for other causes, such as the 2009 H1N1 influenza pandemic. Although it impacts all age groups in terms of disability, the most affected group are people over 50 years of age, whose risk of death is higher.

Correction to: A survival analysis of COVID-19 in the Mexican population.

An amendment to this paper has been published and can be accessed via the original article.

A survival analysis of COVID-19 in the Mexican population.

BACKGROUND: At present, the Americas report the largest number of cases of COVID-19 worldwide. In this region, Mexico is the third country with most deaths (20,781 total deaths). A sum that may be explained by the high proportion of people over 50 and the high rate of chronic diseases. The aim of this analysis is to investigate the risk factors associated with COVID-19 deaths in Mexican population using survival analysis. METHODS: Our analysis includes all confirmed COVID-19 cases contained in the dataset published by the Epidemiological Surveillance System for Viral Respiratory Diseases of the Mexican Ministry of Health. We applied survival analysis to investigate the impact of COVID-19 on the Mexican population. From this analysis, we plotted Kaplan-Meier curves, and constructed a Cox proportional hazard model. RESULTS: The analysis included the register of 16,752 confirmed cases of COVID-19 with mean age 46.55 ± 15.55 years; 58.02% (n = 9719) men, and 9.37% (n = 1569) deaths. Male sex, older age, chronic kidney disease, pneumonia, hospitalization, intensive care unit admission, intubation, and health care in public health services, were independent factors increasing the risk of death due to COVID-19 (p < 0.001). CONCLUSIONS: The risk of dying at any time during follow-up was clearly higher for men, individuals in older age groups, people with chronic kidney disease, and people hospitalized in public health services.

Risk of developing pre-diabetes or diabetes over time in a cohort of Mexican health workers.

AIM: To determine the association between known risk factors (e.g., obesity, metabolic syndrome and its components) and the development of pre-diabetes or diabetes over time in a cohort of Mexican health workers. METHODS: Participants in the Mexican Health Worker Cohort Study with complete information at two waves of data collection, 2004-2006 (W1) and 2011-2013 (W2), were included in the analysis (n = 1,174). Multivariable binary and multinomial logistic regression were used to examine the cross-sectional associations between specific risk factors and diabetes status (diabetes, pre-diabetes, or neither) at W1 and the longitudinal associations between changes in risk factors and progression of diabetes status from W1 to W2, respectively. RESULTS: Mean time between waves was 7.0 years (SD 1.1). Prevalence of pre-diabetes and diabetes was 16% and 10% at W1 and increased to 30% and 16% at W2, respectively. The cross-sectional prevalence of pre-diabetes and diabetes was significantly higher among men, participants over the age of 45 years, and individuals who were overweight or obese or had metabolic syndrome (MS), three or more components of the MS, elevated alanine aminotransferase (ALT) levels, or elevated uric acid. In longitudinal analyses, remaining obese or gaining weight between waves was associated with an increased risk of developing pre-diabetes. A greater risk of developing pre-diabetes or diabetes was also observed among individuals who either maintained or acquired MS, elevated ALT, or elevated uric acid (only for diabetes) from W1 to W2. CONCLUSIONS: Weight gain and acquiring or maintaining MS, elevated ALT levels, or elevated uric acid were associated with a significant risk of developing pre-diabetes or diabetes. Our findings, especially in the context of the obesity epidemic in Mexico, point towards an urgent need for initiatives to help reduce excess weight in order to avert future cases of pre-diabetes and diabetes.

The measurement scale of resilience among family caregivers of children with cancer: a psychometric evaluation.

BACKGROUND: Resilience to disease is a process of positive adaptation despite the loss of health, it involves the development of vitality and skills to overcome the negative effects of adversity, risks, and vulnerability caused by disease. In Mexico, cancer is the leading cause of death in children. Both the diagnosis and the treatment of childhood cancer affect the health of family caregivers. However, resilience is a personality trait that can be protective in these situations. Therefore, resilience is an important psychological construct to measure, evaluate and develop in specific populations and contexts. In Mexico, a scale to assess this trait has been developed. This study aimed to test the reliability and factor structure of the Mexican Measurement Scale of Resilience (RESI-M), describe its distribution, evaluate its relationship with sociodemographic variables, and verify its concurrent validity with psychological well-being, depression, anxiety and parental stress and its independence from social desirability. METHODS: A cross-sectional study was conducted involving an intentional nonprobability sample of 330 family caregivers of children with cancer hospitalized at the National Institute of Health in Mexico City. The participants responded to a sociodemographic variables questionnaire, the Mexican Measurement Scale of Resilience RESI-M, and five other assessment scales. RESULTS: Overall internal consistency was very high (ordinal alpha = .976). The confirmatory factor analysis demonstrated that the five-factor model had a close fit to the data: NFI = .970, CFI = .997, SRMR = .055, and RMSEA = .019. The distributions of the RESI-M total score followed a normal distribution. The RESI-M total score correlated positively with psychological well-being and negatively with depression, parental stress and anxiety. The overall RESI-M total score also correlated positively with age, but there was no difference in means between women and men. Resilience was independent of social desirability. CONCLUSIONS: The RESI-M shows reliability and construct validity in family caregivers of children with cancer and does not show a bias in relation to social desirability.

The impact of poor oral health on the oral health-related quality of life (OHRQoL) in older adults: the oral health status through a latent class analysis.

BACKGROUND: Determine the impact of poor oral health on the oral health-related quality of life (OHRQoL) in community-dwelling older adults. METHODS: Cross-sectional study of community-dwelling older adults in Mexico City. Sociodemographic characteristics were obtained and assessed their OHRQoL according to the Geriatric/General Oral Health Assessment Index (GOHAI). Clinical evaluation of their oral health: painful chewing, use of dentures, dry mouth, xerostomia, plaque, calculus, coronal and root caries, tooth loss and gingival bleeding. Finally, we determined the oral health of participants through Latent Class Analysis (LCA), excluding totally edentulous. The strength of association was determined (Odds Ratio [OR] and 95% confidence interval [95% CI]) through logical regression between the oral health categories (latent classes) and OHRoL in older adults, adjusted with the other variables included in the study: age, sex, marital status, living arrangements (lives alone), educational level, paid work status, comorbidity, cognitive deterioration, depression and use of medical and dental services in the previous 12 months. RESULTS: The mean (SD) GOHAI score for the 228 older adults to 46.5 (8.7), number of classes to characterize oral health through LCA was three (entropy 0.805). The GOHAI mean for Class 3 (57.0%), acceptable oral health was 50.1 (7.1); totally edentulous (9.6%), 47.9 (8.4); for Class 2 (16.7%), regular oral health, 43.8 (9.3); and for Class 1 (16.7%), poor oral health, 42.2 (9.7). Significant differences were observed among means (p < .001). Using Class 3 an as a reference, the strength of association between the GOHAI scores and low OHRQoL (GOHAI 25th percentile = 24.0) was OR = 0.7, 95% CI = 0.2-3.3 for totally edentulous; OR = 3.0, 95% CI = 1.2-7.6 for Class 2 and OR = 5.0, 95% CI = 2.1-12.1 for Class 1. CONCLUSION: Poor oral health was associated with a negative impact on the OHRQoL of community-dwelling older adults. CLINICAL RELEVANCE: It is essential to design and implement oral health care policies specifically targeted at improving the quality of life in this older adult population.

Medical Cost to Treat Cervical Cancer Patients at a Social Security Third Level Oncology Hospital in Mexico City

Background: Cervical Cancer (CC) is an important public health problem worldwide. In 2015, CC was the sixth leading cause of death for women aged 30-59 years in Mexico. Despite the importance of having high-quality and accurate estimates of CC treatment costs that can be used to effectively evaluate the impact of preventive programs, there is scarce information on this topic in Mexico. Objective: To estimate the treatment costs by stage diagnosis in patients with CC at a Mexican Social Security Institute (IMSS) oncology hospital in Mexico City. Methods: An observational retrospective study of the resources used to treat 346 women with CC was conducted. Medical charts were reviewed and relevant resource use information was extracted using a data collection instrument that was created based on treatment guidelines. Data were classified into nine cost categories to estimate the total cost per patient. Results: The mean age of patients in the study sample was 54.3 years (range: 41-67), and the average body mass index (BMI) was >26 kg/m2. Among the participants, 37% were smokers, 39% had diabetes, and 56% had hypertension. The medical cost for stages I-IV ranged from $4,738 to $6,058 USD, with an estimated average cost of $5,114 USD. Conclusion: Total treatment costs per patient are high, especially since they were estimated considering only 7.5 months of treatment. This is the first study to estimate the annual cost to treat CC in Mexico and to additionally document the resource pattern use, cost by stage of cancer, and the distribution by cost categories.